Allakos announced positive results from the single and multiple ascending Phase 1 study of intravenous I AK006 in healthy volunteers. AK006 is a Siglec-6 monoclonal antibody that selectively inhibits mast cells. Inappropriate activation of mast cells has been identified as a pathogenic driver of multiple diseases, including chronic spontaneous urticaria, food allergy and asthma.Phase 1 Study Results: Single and multiple IV doses of AK006 up to 720 mg were well tolerated with a favorable safety profile. AK006 showed dose linear exposure and with an estimated half-life of 21 days for the 720 mg IV dose…AK006 achieved serum concentrations consistent with those showing mast cell inhibition in preclinical experiments
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLK:
- Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
- Allakos announces first patient dosed in Phase 1 trial of AK006
- Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
- Allakos reports Q1 EPS (81c), consensus (47c)
- Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
Questions or Comments about the article? Write to editor@tipranks.com